Solid Biosciences on deck for IPO
Jan. 2, 2018 3:44 PM ET|By: Douglas W. House, SA News Editor
Cambridge, MA-based Solid Biosciences (Pending:SLDB) has filed a preliminary prospectus for a $100M IPO.
The life sciences firm says its mission is to cure Duchenne muscular dystrophy (DMD). Lead candidate is SGT-001, a gene transfer that restores functional dystrophin protein expression in muscles by delivering a synthetic transgene that produces dystrophin-like protein. The delivery vector is an adeno-associated virus (AAV) that contains a muscle-specific promoter.
SGT-001 has Rare Pediatric Disease and Orphan Drug designations in the U.S. A Phase 1/2 study, IGNITE DMD, was initiated last quarter. According to ClinicalTrials.gov, the estimated primary completion date is March 2020.
2017 Financials (9 mo.)($M): Operating Expenses: 39.7 (+134.9%); Net Loss: (39.7) (-134.9%); Cash Burn: (29.2) (-101.4%).
DMD-related tickers: SRPT BIIB CAPR WVE PTCT CATB SMMT BMRN
Market Data 
Markets 
